Business Wire

Paracrine Announces Publication of STAR Trial, Including Improvement in Hand Function and Quality of Life in Patients With Diffuse Cutaneous Scleroderma

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...
Business Wire

Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients With Hand Dysfunction Due to Diffuse Cutaneous Scleroderma

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...
Monthly Prescribing Reference

Subclinical Atherosclerosis Noted in Diffuse Scleroderma

(HealthDay News) – Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis. To identify signs of early ...
Labroots

Scientists Find a Biomarker for Better Scleroderma Detection

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.
Mena FN

Scleroderma Therapeutics Market To Reach USD 4.49 Billion By 2035 Rising Focus On Targeted Therapies And Advancements In Autoimmune Disease Research Driving Market Growth SNS ...

(MENAFN- GlobeNewsWire - Nasdaq) Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion. Austin, United States, March 19, ...